Strengthening the case for gender-neutral and the nonavalent HPV vaccine.

about

Strengthening the case for gender-neutral and the nonavalent HPV vaccine.

Item

http://www.wikidata.org/entity/Q47554428

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Strengthening the case for gender-neutral and the nonavalent HPV vaccine.

@en

Strengthening the case for gender-neutral and the nonavalent HPV vaccine.

@nl

type

Item

label

Strengthening the case for gender-neutral and the nonavalent HPV vaccine.

@en

Strengthening the case for gender-neutral and the nonavalent HPV vaccine.

@nl

prefLabel

Strengthening the case for gender-neutral and the nonavalent HPV vaccine.

@en

Strengthening the case for gender-neutral and the nonavalent HPV vaccine.

@nl

P1476

Strengthening the case for gender-neutral and the nonavalent HPV vaccine.

@en

P2093

James P O'Neill

http://www.w3.org/2001/XMLSchema#string

P2860

Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

The "new" head and neck cancer patient-young, nonsmoker, nondrinker, and HPV positive: evaluation

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

HPV vaccination to prevent oropharyngeal carcinoma: What can be learned from anogenital vaccination programs?

Case-control study of human papillomavirus and oropharyngeal cancer

A review of human carcinogens--Part B: biological agents

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

P2888

s00405-018-4866-y

P304

857-865

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00405-018-4866-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

275

http://www.w3.org/2001/XMLSchema#string

P50

Justin M Hintze

P577

2018-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29327306

http://www.w3.org/2001/XMLSchema#string